Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

被引：2
|
作者：
Tanioka, M.
Fan, C.
Carey, L. A.
Hyslop, T.
Pitcher, B. N.
Parker, J. A.
Hoadley, K. A.
Henry, N. L.
Tolaney, S.
Dang, C.
Krop, I. E.
Harris, L.
Berry, D. A.
Mardis, E.
Perou, C. M.
Winer, E. P.
Hudis, C. A.
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] NCI, Bethesda, MD 20892 USA
[7] Alliance Stat & Data Ctr MD Anderson, Houston, TX USA
[8] Washington Univ, St Louis, MO USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-S3-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S3-05
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
    Hoadley, Katherine A.
    Barry, William T.
    Pitcher, Brandelyn N.
    Parker, Joel S.
    Wilkerson, Matthew D.
    Irvin, William, Jr.
    Henry, Norah Lynn
    Tolaney, Sara M.
    Dang, Chau
    Krop, Ian E.
    Berry, Donald A.
    Mardis, Elaine R.
    Perou, Charles M.
    Winer, Eric P.
    Hudis, Clifford A.
    Carey, Lisa A.
    CANCER RESEARCH, 2015, 75
  • [2] Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.
    Carey, Lisa A.
    Berry, Donald A.
    Ollila, David
    Harris, Lyndsay
    Krop, Ian E.
    Weckstein, Douglas
    Henry, Norah Lynn
    Anders, Carey K.
    Cirrincione, Constance
    Winer, Eric P.
    Perou, Charles M.
    Hudis, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
    Fernandez-Martinez, Aranzazu
    Krop, Ian E.
    Hillman, David W.
    Polley, Mei-Yin
    Parker, Joel S.
    Huebner, Lucas
    Hoadley, Katherine A.
    Shepherd, Jonathan
    Tolaney, Sara
    Henry, N. Lynn
    Dang, Chau
    Harris, Lyndsay
    Berry, Donald
    Hahn, Olwen
    Hudis, Clifford
    Winer, Eric
    Partridge, Ann
    Perou, Charles M.
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (35) : 4184 - +
  • [4] Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).
    Carey, Lisa A.
    Barry, William Thomas
    Pitcher, Brandy
    Hoadley, Katherine A.
    Cheang, Maggie Chon U.
    Anders, Carey K.
    Henry, N. Lynn
    Tolaney, Sara M.
    Dang, Chau T.
    Krop, Ian E.
    Harris, Lynd Say
    Berry, Donald A.
    Perou, Charles M.
    Winer, Eric P.
    Hudis, Clifford A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
    Tanioka, Maki
    Fan, Cheng
    Parker, Joel S.
    Hoadley, Katherine A.
    Hu, Zhiyuan
    Li, Yan
    Hyslop, Terry M.
    Pitcher, Brandelyn N.
    Soloway, Matthew G.
    Spears, Patricia A.
    Henry, Lynn N.
    Tolaney, Sara
    Dang, Chau T.
    Krop, Ian E.
    Harris, Lyndsay N.
    Berry, Donald A.
    Mardis, Elaine R.
    Winer, Eric P.
    Hudis, Clifford A.
    Carey, Lisa A.
    Perou, Charles M.
    CLINICAL CANCER RESEARCH, 2018, 24 (21) : 5292 - 5304
  • [6] Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
    Carey, Lisa A.
    Berry, Donald A.
    Cirrincione, Constance T.
    Barry, William T.
    Pitcher, Brandelyn N.
    Harris, Lyndsay N.
    Ollila, David W.
    Krop, Ian E.
    Henry, Norah Lynn
    Weckstein, Douglas J.
    Anders, Carey K.
    Singh, Baljit
    Hoadley, Katherine A.
    Iglesia, Michael
    Cheang, Maggie Chon U.
    Perou, Charles M.
    Winer, Eric P.
    Hudis, Clifford A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 542 - +
  • [7] Neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER). Analysis of biomarkers
    Fernandez, M.
    Martinez, N.
    Calvo, I.
    Garcia, E.
    Ugidos, L.
    Herrero, M.
    Quijano, Y.
    Duran, H.
    Garcia, M.
    Suarez, A.
    Lopez-Rios, F.
    Perez, D.
    Perea, S.
    Hidalgo, M.
    Garcia-Estevez, L.
    CANCER RESEARCH, 2013, 73
  • [8] Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)
    Mehra Golshan
    Constance T. Cirrincione
    William M. Sikov
    Lisa A. Carey
    Donald A. Berry
    Beth Overmoyer
    Nora L. Henry
    George Somlo
    Elisa Port
    Harold J. Burstein
    Clifford Hudis
    Eric Winer
    David W. Ollila
    Breast Cancer Research and Treatment, 2016, 160 : 297 - 304
  • [9] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Takahashi, M.
    Hayashida, T.
    Sakata, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC).
    Iyengar, Neil M.
    Fornier, Monica Nancy
    Sugarman, Steven
    Theodoulou, Maria
    Troso-Sandoval, Tiffany A.
    D'Andrea, Gabriella
    Drullinsky, Pamela
    Fasano, Julie
    Gajria, Devika
    Goldfarb, Shari Beth
    Comen, Elizabeth Anne
    Lake, Diana
    Modi, Shanu
    Traina, Tiffany A.
    Chen, Melanie
    Patil, Sujata
    Baselga, Jose
    Norton, Larry
    Hudis, Clifford A.
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345